KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Cash (2016 - 2025)

BeOne Medicines (ONC) has disclosed Change in Cash for 11 consecutive years, with $1.3 billion as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 1286.91% to $1.3 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 billion, a 480.2% increase, with the full-year FY2024 number at -$547.2 million, up 20.58% from a year prior.
  • Change in Cash was $1.3 billion for Q3 2025 at BeOne Medicines, up from $255.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $3.4 billion in Q4 2021 to a low of -$1.8 billion in Q4 2022.
  • A 5-year average of $86.6 million and a median of -$108.2 million in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: soared 4344.29% in 2021, then plummeted 1064.93% in 2023.
  • BeOne Medicines' Change in Cash stood at $3.4 billion in 2021, then plummeted by 152.92% to -$1.8 billion in 2022, then skyrocketed by 105.87% to $105.1 million in 2023, then tumbled by 171.06% to -$74.7 million in 2024, then soared by 1873.48% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Change in Cash are $1.3 billion (Q3 2025), $255.5 million (Q2 2025), and -$108.2 million (Q1 2025).